Kaitlyn D’Onofrio

DocwireNews

A study examined factors associated with multiple failures to <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/healthcare-visits-dmard-treatment-both-interrupted-for-autoimmune-rheumatic-patients-during-covid-19/">biologic disease-modifying antirheumatic drugs (bDMARDs)</a> among patients with <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/tocilizumab-effectiveness-not-impacted-by-obesity-in-patients-with-ra/">rheumatoid arthritis</a> (RA). They concluded that younger age and the presence of erosions were independent risk factors.&ldquo;Nowadays, despite the increasing number of therapeutic tools available, the successful treatment of certain RA patients remains particularly challenging for clinicians,&rdquo; the authors explained in their reasoning for undertaking the study. &ldquo;This is in part due to the severity of the disease, but additionally may be related to the tendency of rheumatologists to cycle or switch therapies in an attempt to achieve strict disease control, following the treat-to-target recommendations. The percentage of patients who fail to respond to multiple bDMARDs in clinical practice is sufficiently relevant to warrant special focus due to the intrinsic difficulties of achieving good disease control.&rdquo;Patients with RA were identified from the La Paz University Hospital RA Registry. All patients in the current analysis started a bMARD between 2000 and 2019. Multi-refractory patients (MR-patients) were those who had an insufficient response to at least three bDMARDs or two bDMARDs that had different mechanism of action. Non-refractory patients (NR-patients) were those who attained low disease activity or remission, per the Disease Activity Score in 28 joints (DAS-28), with the first bDMARD and maintained it for at least five years.Of 402 total patients identified, 41 were MR-patients (10%) and 71 were NR-patients (18%). The following factors were independently correlated with being MR-patients to bDMARDs on multivariate analysis: being younger (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.90&ndash;0.99), presence of erosions (OR, 3.26; 95% CI, 1.18&ndash;9.00), and higher baseline DAS-28 (OR, 2.29; 95% CI, 1.39&ndash;3.76) before initiating the first bDMARD, and achieving a delta-DAS-28 &lt;1.2 six&thinsp;months after initiating the first bDMARD (OR, 11.12; 95% CI, 3.34&ndash;26.82).The study was published in <a href="https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-020-02354-1">Arthritis Research &amp; Therapy</a>.The researchers stated in their conclusion that &ldquo;our findings highlight the fact that a universal standard definition of multi-refractoriness is needed if further studies are going to be capable of establishing predictors to multiple bDMARD failure.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Which Patients With Rheumatoid Arthritis Are More Likely to Experience Multiple Biologic Failures?

Rheumatoid Arthritis

A study examined factors associated with multiple failures to biologic disease-modifying antirheumatic drugs (bDMARDs) among patients with rheumatoid arthritis (RA). They ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe